- Immuron Limited (IMRN, Financial) records highest sales in history for Travelan®, exceeding AUD$5.3 million YTD, marking a 46% increase year-over-year.
- Strong North American growth with an 86% increase in sales YTD, while Australian sales rose by 34% despite a quarterly decline.
- Travelan® ranks #1 by market share change in Australia’s Anti-diarrheal category, demonstrating successful market positioning.
Immuron Limited (IMRN), an Australian biopharmaceutical company, has achieved unprecedented sales figures for its over-the-counter immune supplement, Travelan®. Global sales have surpassed AUD$5.3 million year-to-date, reflecting a 46% increase compared to the same period last year, marking the best sales performance in the company’s history.
Regional growth was particularly strong in North America, where quarterly sales soared by 28% to reach AUD$0.5 million. Year-to-date sales in this region climbed 86% to AUD$1.6 million, underpinning the company's successful market strategies. In Australia, sales for the March 2025 quarter dipped by 8% to AUD$0.8 million; however, year-to-date figures showcased a 34% increase, totaling AUD$3.7 million. The product has achieved a significant position in the Australian market, ranking #1 by market share change in the Anti-diarrheal category.
Travelan®'s strategic growth has been fueled by expanded pharmacy banner agreements in Australia, direct-to-consumer marketing successes in the USA, and inclusion in major retailer listings in Canada. With projections for further growth driven by upcoming travel seasons in both hemispheres, Immuron is poised to continue its upward sales trajectory.
